Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-038441
Filing Date
2025-03-13
Accepted
2025-03-13 11:43:20
Documents
20
Period of Report
2025-03-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A mcrb-20250313.htm   iXBRL DEF 14A 2152909
2 GRAPHIC img116574093_0.jpg GRAPHIC 117747
3 GRAPHIC img116574093_1.jpg GRAPHIC 65052
4 GRAPHIC img116574093_2.jpg GRAPHIC 183714
5 GRAPHIC img116574093_3.jpg GRAPHIC 293329
6 GRAPHIC img116574093_4.jpg GRAPHIC 65052
7 GRAPHIC img116574093_5.jpg GRAPHIC 511520
8 GRAPHIC img116574093_6.jpg GRAPHIC 235249
  Complete submission text file 0000950170-25-038441.txt   6326038

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mcrb-20250313.xsd EX-101.SCH 15866
22 EXTRACTED XBRL INSTANCE DOCUMENT mcrb-20250313_htm.xml XML 151643
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37465 | Film No.: 25734528
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)